Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




May
14
Today In Oncology
Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC
Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers
Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL
FDA Approves Combination Regimen for Newly Diagnosed AML
Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo